JP2009508876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009508876A5 JP2009508876A5 JP2008531431A JP2008531431A JP2009508876A5 JP 2009508876 A5 JP2009508876 A5 JP 2009508876A5 JP 2008531431 A JP2008531431 A JP 2008531431A JP 2008531431 A JP2008531431 A JP 2008531431A JP 2009508876 A5 JP2009508876 A5 JP 2009508876A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutical composition
- alkyl
- independently
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 241000124008 Mammalia Species 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 230000004770 neurodegeneration Effects 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 230000004766 neurogenesis Effects 0.000 claims 7
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 230000000638 stimulation Effects 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 239000000651 prodrug Chemical group 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- -1 3-quinolinylmethyl Chemical group 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71869105P | 2005-09-19 | 2005-09-19 | |
| US60/718,691 | 2005-09-19 | ||
| US82220206P | 2006-08-11 | 2006-08-11 | |
| US60/822,202 | 2006-08-11 | ||
| PCT/US2006/036463 WO2007035722A2 (en) | 2005-09-19 | 2006-09-19 | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009508876A JP2009508876A (ja) | 2009-03-05 |
| JP2009508876A5 true JP2009508876A5 (enExample) | 2009-11-05 |
| JP5554496B2 JP5554496B2 (ja) | 2014-07-23 |
Family
ID=37889462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008531431A Active JP5554496B2 (ja) | 2005-09-19 | 2006-09-19 | 神経発生を刺激するための、およびニューロン変性を阻害するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8039462B2 (enExample) |
| EP (1) | EP1937252B1 (enExample) |
| JP (1) | JP5554496B2 (enExample) |
| KR (2) | KR101158568B1 (enExample) |
| CN (3) | CN102743382B (enExample) |
| AU (1) | AU2006292256B2 (enExample) |
| CA (2) | CA2623507C (enExample) |
| DK (1) | DK1937252T3 (enExample) |
| IL (3) | IL190179A (enExample) |
| PL (1) | PL1937252T3 (enExample) |
| RU (1) | RU2440346C2 (enExample) |
| WO (1) | WO2007035722A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623507C (en) * | 2005-09-19 | 2013-03-12 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| RU2549441C2 (ru) * | 2009-09-22 | 2015-04-27 | Ньюронасент, Инк. | Способы и фармацевтические композиции для лечения синдрома дауна |
| CA2754237A1 (en) * | 2011-05-27 | 2012-11-27 | The Regents Of The University Of California | Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof |
| KR102074530B1 (ko) * | 2012-03-06 | 2020-02-06 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 조합 요법에 의한 프로카스파제 ３ 활성화 |
| CA2917628A1 (en) * | 2013-09-12 | 2015-03-19 | F. Hoffmann-La Roche Ag | Indol-carboxamide derivatives |
| RU2630654C2 (ru) * | 2015-07-29 | 2017-09-11 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Балтийский Федеральный Университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ хемогенетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции астроцитов и нейронов |
| RU2670128C2 (ru) * | 2016-12-16 | 2018-10-18 | Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) | Способ генетической регистрации и коррекции нейрогенеза на основе генетических конструкций для трансфекции нейронов |
| KR20190081385A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| KR20190081386A (ko) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | 루핀아마이드를 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| EP4352058A4 (en) * | 2021-06-11 | 2025-09-24 | Neuronascent Inc | METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF SMALL MOLECULE THERAPIES WITH LIPOPHILIC HETEROCYCLIC TYPES |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3571489A (en) * | 1966-12-23 | 1971-03-16 | Max Levy & Co Inc | Transparent substrate having graded optical density conductors thereon |
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3612745A (en) * | 1970-07-08 | 1971-10-12 | Sierracin Corp | Flexural bus bar assembly |
| US4057671A (en) * | 1975-06-27 | 1977-11-08 | Ppg Industries, Inc. | Heated laminated window and method of assembling same |
| US4089809A (en) * | 1976-03-01 | 1978-05-16 | The United States Of America As Represented By The United States Department Of Energy | Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures |
| US4233871A (en) * | 1978-04-26 | 1980-11-18 | Alessi Anthony A | Notching tool |
| ATE8584T1 (de) * | 1980-01-16 | 1984-08-15 | Hans Georg Prof. Dr. Weder | Verfahren und dialysiereinrichtung zur herstellung von bilayer-vesikeln und verwendung der bilayer-vesikel. |
| US4323726A (en) * | 1980-07-24 | 1982-04-06 | Ppg Industries, Inc. | Electrical bus bar assembly |
| US4361751A (en) * | 1980-07-24 | 1982-11-30 | Ppg Industries, Inc. | Electroconductive window having improved bus bar |
| US4656174A (en) * | 1982-07-24 | 1987-04-07 | Pfizer Inc. | Quinoline therapeutic agents |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4438253A (en) * | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
| US4540786A (en) * | 1983-08-22 | 1985-09-10 | The Dow Chemical Company | Preparation of 2-chloro-3-cyano-quinolines |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4532089A (en) * | 1984-01-14 | 1985-07-30 | Northwestern University | Method of preparing giant size liposomes |
| US4897269A (en) * | 1984-09-24 | 1990-01-30 | Mezei Associates Limited | Administration of drugs with multiphase liposomal delivery system |
| JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| GB9425986D0 (en) * | 1994-12-22 | 1995-02-22 | Pilkington Glass Ltd | Electrically heated window |
| US5820880A (en) * | 1995-06-07 | 1998-10-13 | The United States Of America As Represented By The Secretary Of The Army | Liposomal formulation |
| US5665428A (en) * | 1995-10-25 | 1997-09-09 | Macromed, Inc. | Preparation of peptide containing biodegradable microspheres by melt process |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| RU2221785C2 (ru) * | 1998-09-22 | 2004-01-20 | Яманоути Фармасьютикал Ко., Лтд. | Гетероциклическое производное, фармацевтическая композиция, его содержащая, и промежуточный продукт |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| US6287588B1 (en) * | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| CA2372782A1 (en) * | 1999-05-11 | 2000-11-16 | Wing Cheung | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| AU2001293207A1 (en) * | 2000-08-18 | 2002-03-04 | Cor Therapeutics, Inc. | Nitrogenous heterocyclic compounds |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| CN1678586A (zh) * | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
| EP1608373A4 (en) * | 2003-03-19 | 2010-09-29 | Exelixis Inc | TIE-2 MODULATORS AND USE METHOD |
| US20070128905A1 (en) * | 2003-06-12 | 2007-06-07 | Stuart Speakman | Transparent conducting structures and methods of production thereof |
| CA2623507C (en) * | 2005-09-19 | 2013-03-12 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
-
2006
- 2006-09-19 CA CA2623507A patent/CA2623507C/en active Active
- 2006-09-19 US US12/066,640 patent/US8039462B2/en active Active
- 2006-09-19 DK DK06803851.2T patent/DK1937252T3/da active
- 2006-09-19 CA CA2800945A patent/CA2800945C/en active Active
- 2006-09-19 EP EP06803851.2A patent/EP1937252B1/en active Active
- 2006-09-19 RU RU2008109821/04A patent/RU2440346C2/ru active
- 2006-09-19 CN CN201210246309.XA patent/CN102743382B/zh active Active
- 2006-09-19 JP JP2008531431A patent/JP5554496B2/ja active Active
- 2006-09-19 PL PL06803851T patent/PL1937252T3/pl unknown
- 2006-09-19 CN CN201610900496.7A patent/CN106474118A/zh active Pending
- 2006-09-19 CN CN2006800414246A patent/CN101304743B/zh active Active
- 2006-09-19 KR KR1020117015480A patent/KR101158568B1/ko active Active
- 2006-09-19 KR KR1020087009255A patent/KR101132378B1/ko active Active
- 2006-09-19 WO PCT/US2006/036463 patent/WO2007035722A2/en not_active Ceased
- 2006-09-19 AU AU2006292256A patent/AU2006292256B2/en active Active
-
2008
- 2008-03-16 IL IL190179A patent/IL190179A/en active IP Right Grant
-
2011
- 2011-09-13 US US13/231,584 patent/US8999972B2/en active Active
-
2014
- 2014-02-04 IL IL230807A patent/IL230807B/en not_active IP Right Cessation
-
2015
- 2015-04-06 US US14/679,874 patent/US9539261B2/en active Active
-
2017
- 2017-12-21 IL IL256489A patent/IL256489A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9199979B2 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| CA2868958C (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| RU2376287C2 (ru) | Производные бензамида, способ их получения и их применение, фармацевтическая композиция и способ обеспечения ингибирующего действия по отношению к hdac | |
| JP2007517807A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2009542716A5 (enExample) | ||
| JP2008526999A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| CA2416274A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2008509187A5 (enExample) | ||
| US10023534B2 (en) | Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK | |
| HRP20231533T1 (hr) | Kristalni oblici od (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4 ]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina i postupci priprave | |
| JP2013514980A5 (enExample) | ||
| JPWO2021053555A5 (enExample) | ||
| JP2009508876A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2016525104A5 (enExample) | ||
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| JP2011518168A5 (enExample) | ||
| JP2005538974A5 (enExample) | ||
| JP2005532397A5 (enExample) | ||
| JP2016523830A5 (enExample) | ||
| RU2008109821A (ru) | Способ и композиция для стимуляции нейрогенеза и ингибирования дегенерации нейронов |